Drug class
Antimetabolite immunosuppressant; prodrug of mycophenolic acid (MPA)
Mechanism of action
After absorption, mycophenolate mofetil is hydrolysed to mycophenolic acid, a selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This inhibits de-novo guanosine nucleotide synthesis and suppresses proliferation of T and B lymphocytes.
General use cases
- Prophylaxis of organ rejection in adult and paediatric recipients aged 3 months and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants; not a stand-alone treatment for graft-versus-host disease or psoriasis
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
